Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Accounts Payables: 2013-2025

Historic Accounts Payables for Theravance Biopharma (TBPH) over the last 12 years, with Sep 2025 value amounting to $2.2 million.

  • Theravance Biopharma's Accounts Payables rose 52.20% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 52.20%. This contributed to the annual value of $2.2 million for FY2024, which is 47.11% up from last year.
  • Latest data reveals that Theravance Biopharma reported Accounts Payables of $2.2 million as of Q3 2025, which was up 32.12% from $1.7 million recorded in Q2 2025.
  • Theravance Biopharma's Accounts Payables' 5-year high stood at $10.7 million during Q2 2021, with a 5-year trough of $1.5 million in Q3 2024.
  • Its 3-year average for Accounts Payables is $2.0 million, with a median of $1.7 million in 2024.
  • Per our database at Business Quant, Theravance Biopharma's Accounts Payables slumped by 77.90% in 2022 and then spiked by 76.36% in 2023.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Accounts Payables stood at $3.1 million in 2021, then plummeted by 49.84% to $1.6 million in 2022, then fell by 1.93% to $1.5 million in 2023, then spiked by 47.11% to $2.2 million in 2024, then surged by 52.20% to $2.2 million in 2025.
  • Its Accounts Payables stands at $2.2 million for Q3 2025, versus $1.7 million for Q2 2025 and $2.4 million for Q1 2025.